Biomarkers in Bipolar Disorders summarizes cutting-edge findings in biomarkers' research, emphasizing the most promising findings, tools and technologies relevant to drug development and personalized medicine. Key findings cover different levels of evidence such as genes, molecules, cells, systems, brain and behavior related to diagnosis (state and trait/endophenotypes), prediction of treatment response and follow-up outcomes, along with the most promising perspectives in each area. Each section includes a comprehensive and focused overview on the state-of-the-art and perspectives. The book concludes with a section on practical applications, encompassing diagnostics development (genetic testing, biomarkers), and new drug development. Edited by Dr. Rodrigo Machado-Vieira and Dr. Jair C. Soares, and contributed by leading experts in the field of biomarker research, this book will be become the leading tool for all researchers and clinicians in Bipolar Disorder. - Describes strategies for the biomarker discovery of relevant proteins differentially expressed in Bipolar Disorder - Presents techniques and main findings in transcriptome research related to CNS synaptic function - Provides an overview on current behavioral strategies and their validity in drug development in Bipolar Disorder - Discusses current genetic findings, integrating tests for treatments leading to personalized treatments

Clinicians searching for evidence-based quantitative assessments on which to base diagnosis and treatment of patients with bipolar disorder need look no further. Advances in Treatment of Bipolar Disorders analyzes the benefits and harms for both older and more recently developed treatments, and places these analyses in the context of the authors' many years of clinical experience. The result is a book that is both quantitatively sound and qualitatively rich, and one that will help clinicians understand the latest research and integrate it into their practices with confidence. In addition to comprehensive coverage of the most important recent advances, the book addresses advances in more specific areas, including the treatment of particular populations such as women, children, and older adults. In addition, the book covers many critically important topics and boasts an abundance of helpful features: Evidence-based quantitative assessments of benefits use "numbers needed to treat" for therapeutic effects and "numbers needed to harm" for side effects, ensuring that the quality of data supporting interventions meets a rigorous standard. The book's information is based not only on controlled trials and FDA approvals but also on almost two decades of clinical research and clinical treatment experience by clinicians at Stanford University. Plentiful figures and summary tables are provided to summarize the content and make it easy-to-grasp and clinician-friendly. In addition to coverage of acute bipolar depression and acute manic and mixed episodes, the book provides chapters on the preventive treatment of bipolar disorder and the pharmacology of mood-stabilizing and second-generation antipsychotic medications. Bipolar disorders are challenging and complex mental illnesses, and clinicians need all the help they can get in managing the effects of these illness on their patients' lives. Advances in Treatment of Bipolar Disorders aims to provide everything clinicians need to know to update their knowledge of this rapidly evolving field and ensure an evidence-based standard of care for this patient population.

The Neurobiology of Bipolar Disorder: Road to Novel Therapeutics combines the basic neurobiology of bipolar disorder with discussions of the most recent advances in research, including the interacting pathways implicated in the pathophysiology of bipolar disorder, genetic approaches and the pharmacogenomics of bipolar disorder. The basic foundational understanding of the neurobiology underlying the disorder, along with a comprehensive summary of the most recent advances in research combine to aid advanced students and researchers in their understanding of bipolar disorder management using novel and fast-acting pharmaceutical and neuromodulatory approaches. - Aids readers in understanding bipolar disorder in the context of NIMH Research Domain Criteria (RDoC) recommendations - Covers a range of existing and potential pharmacologic and non-pharmacologic treatment options, from lifestyle adjustments to novel therapeutics - Synthesizes a discussion of the cellular and molecular mechanisms underlying symptoms with clinical aspects of bipolar disorder

Bipolar Disorders: New Insights for the Healthcare Professional: 2013 Edition is a ScholarlyEditions™ book that delivers timely, authoritative, and comprehensive information about Diagnosis and Screening. The editors have built Bipolar Disorders: New Insights for the Healthcare Professional: 2013 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Diagnosis and Screening in this book to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Bipolar Disorders: New Insights for the Healthcare Professional: 2013 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.

Neuroprogression and Staging in Bipolar Disorder provides a comprehensive and scholarly overview of clinical staging systems in the management of bipolar disorder. The book covers the theoretical basis, the neurobiological underpinnings, the current evidence base, limitations, future directions and the clinical implications and recommendations.

This book includes a series of reviews on general aspects of biomarker use in the study of psychiatric and neurodegenerative diseases and the development of medications involved in their treatment. It describes the pros and cons of the various approaches and covers the successes and failures in this research field. It is only by a thorough understanding of the shortcomings that progress can be made. The overall goal is to facilitate the understanding and treatment of these disorders, by providing a viable mechanism of catching up with other areas of modern medicine, such as diabetes and heart disease. Finally, it is anticipated that the development and application of valid biomarker tests and the leveraging of novel drug targets will help the fields of psychiatry on neurodegenerative disorders move into the area of personalized medicine where the right patients can receive the right medication at the right time for the best possible outcome.

Bipolar Disorders: New Insights for the Healthcare Professional / 2012 Edition is a ScholarlyEditions™ eBook that delivers timely, authoritative, and comprehensive information about Bipolar Disorders. The editors have built Bipolar Disorders: New Insights for the Healthcare Professional / 2012 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Bipolar Disorders in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Bipolar Disorders: New Insights for the Healthcare Professional / 2012 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.

Covers advances in the fields of genetics, neuropsychopharmacology, psychosocial factors, and more, emphasizing therapeutic potential.

Neuropsychiatric disorders such as schizophrenia, mood disorders, Alzheimer’s disease, epilepsy, alcoholism, substance abuse and others are one of the most debilitating illnesses worldwide characterizing by the complexity of the causes, and lacking the laboratory tests that may promote diagnostic and prognostic procedures. Recent advances in neuroscience, genomic, genetic, proteomic and metabolomic knowledge and technologies have opened the way to searching biomarkers and endophenotypes, which may offer powerful and exciting opportunity to understand the etiology and the underlying pathophysiological mechanisms of neuropsychiatric disorders. The challenge now is to translate these advances into meaningful diagnostic and therapeutic advances. This book offers a broad synthesis of the current knowledge about diverse topics of the biomarker and endophenotype strategies in neuropsychiatry. The book is organized into four interconnected volumes: “Neuropsychological Endophenotypes and Biomarkers” (with overview of methodological issues of the biomarker and endophenotype approaches in neuropsychiatry and some technological advances), “Neuroanatomical and Neuroimaging Endophenotypes and Biomarkers”, “Metabolic and Peripheral Biomarkers” and “Molecular Genetic and Genomic Markers”. The contributors are internationally and nationally recognized researchers and experts from 16 countries. This four-volume handbook is intended for a broad spectrum of readers including neuroscientists, psychiatrists, neurologists, endocrinologists, pharmacologists, clinical psychologists, general practitioners, geriatricians, health care providers in the field of neurology and mental health interested in trends that have crystallized in the last decade, and trends that can be expected to further evolve in the coming years. It is hoped that this book will also be a useful resource for the teaching of psychiatry, neurology, psychology and mental health.